Merova, or rituximab injection, is available in a single dosage of 375mg/m^2 to 500mg/m^2 per body surface area. Rituximab Injection is indicated for the treatment of non-Hodgkin’s lymphoma and chronic lymphocytic leukemia, for the former the recommended dosage is 375mg/m^2 per body surface area per dose, while for the latter the recommended dosage is 375mg/m^2 per body surface area per dose for the first course of treatment, and 500mg/m^2 per body surface area per dose for the subsequent courses of treatment. The specific regimen should be determined by a specialist based on the patient’s condition. The drug may cause a variety of bacterial and viral infections, leukopenia, angioedema, nausea, rash, fever and other adverse reactions, and is contraindicated in allergic individuals. The drug should be used under medical supervision. Close observation is required when using the drug, if any adverse reaction occurs after the use of the drug need to consult a doctor in time.